| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96b882006e755dfc56fcabfc5fb019f6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-12 |
| filingDate |
2015-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54dd4ae649c5528c691acf4ffec2c6eb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8848e6320f8366c52d16520c027ccbc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97c52bc7859a8b5d48083fef9cc6f872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc83468f61705c461a292c3edbd6ec9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edaa98532832c887c8e4d8dae8f4a304
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76ddaddb1bdd36c728ab4cd26607ede2 |
| publicationDate |
2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9663500-B2 |
| titleOfInvention |
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
| abstract |
Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098034-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10214518-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10689372-B2 |
| priorityDate |
2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |